Veröffentlichungsdatum: 17 Dezember 2007
Projektträger – zwischengeschaltetes Finanzinstitut
Sanofi-Aventis
Ort
Beschreibung
The project concerns the design, construction or modernisation, and the equipment of several buildings providing facilities for pharmacological research, product development facilities and office space in Europe.
Ziele
The project aims at regrouping and reorganizing the promoter’s R&D activities in order to optimize the use of premises and equipments and facilitate the synergies between different therapeutic areas. It concerns the design, construction or modernisation, and the equipment of several buildings providing facilities for pharmacological research and office space in Europe. The facilities will be located in France, Germany, United Kingdom, Spain and Italy, mostly in the promoter’s existing R&D sites.
Sektor(en)
Vorgeschlagene EIB-Finanzierung (voraussichtlicher Betrag)
EUR 350 million.
Gesamtkosten (voraussichtlicher Betrag)
EUR 999 million.
Umweltaspekte
The sub-projects fall under Annex II of the directive EU/97/11 amended by Directive 2003/35/EC on Environmental Impact Assessment (EIA). The determination made by the competent authorities for requesting (or not) an EIA on the basis of Annex III of the Directive and actual/possible significant impacts on protected flora and fauna (Habitats’ and Birds’ Directives) has been verified during project appraisal.
Auftragsvergabe
The promoter is a private company not operating in the Utilities sector, and is thus not covered by EU Directives on procurement. Procedures followed have been verified during appraisal.
Projektstatus
Unterzeichnet - 13/12/2007
Haftungsausschluss
Bis Finanzierungen vom Verwaltungsrat genehmigt und anschließend unterzeichnet werden, befinden sich die Projekte in der Prüfungs- oder Verhandlungsphase. Die Angaben auf dieser Seite sind daher unverbindlich.
Sie dienen lediglich der Transparenz und stellen nicht die offizielle EIB-Politik dar (vgl. auch die erklärenden Anmerkungen).